Real-World Patient Perspectives on Glipizide and Empagliflozin for Type 2 Diabetes

Background:Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder requiring long-term pharmacological therapy. While Glipizide, a sulfonylurea, remains a common treatment option, newer agents such as Empagliflozin (Jardiance) offer potential additional benefits. Patient-reported experiences may provide valuable insights for optimizing treatment selection. Methods:An anonymous, cross-sectional online survey was conducted among adults with T2DM who had prior exposure to both Glipizide and Empagliflozin. Participants answered four questions addressing perceived glycemic control, satisfaction, and treatment preference. Responses were summarized using descriptive statistics. Results:A total of 39 patients completed the survey. The majority, 33 participants (85%), reported achieving better glycemic control with Glipizide, whereas 6 (15%) favored Empagliflozin. Satisfaction with Empagliflozin was mixed: 12 patients (31%) were disappointed, 20 (51%) were neutral, and 7 (18%) reported happiness with its use. In comparison, Glipizide was rated more positively, with 5 patients (13%) disappointed, 11 (28%) neutral, and 23 (59%) happy. When asked which medication they would recommend, 18 participants (46%) favored Empagliflozin, while 21 (54%) preferred Glipizide. Conclusions:Glipizide was perceived to provide superior glycemic control and greater patient satisfaction compared with Empagliflozin. Nonetheless, nearly half of the participants recommended Empagliflozin despite lower ratings of satisfaction and efficacy. These findings suggest that patient preferences may extend beyond glycemic outcomes alone and highlight the importance of integrating patient-reported experiences into individualized treatment decisions for T2DM.